Connect with us

Wales

Welsh life sciences company eyes expansion in the Middle East

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

A Welsh life sciences company which plays a crucial role in helping to
diagnose and treat cancer around the world has announced plans to expand in
the Middle East as part of a wider strategy to grow the business, thanks to
support from the Welsh Government.

Newtown-based CellPath, which specialises in the manufacture and supply of
equipment and services used in cancer diagnostics, already exports to over
40 countries across Europe, America, Asia, Africa and the Middle East
including the UAE, Qatar and Iraq.

The company has recently secured a number of key distribution agreements
including a partnership with a large US-based equipment supplier, which
will enable CellPath to expand the list of products it is able to offer and
subsequently increase its sales.

It is now looking to double its export turnover in the Middle East and
South Asia territory over the next two years - a key target market thanks
to the region’s rapidly growing medical sector.

Reports by KPMG reveal healthcare expenditure in the UAE has grown from $60
billion in 2013 to $76 billion in 2019, and is expected to rise to a
further $89 billion by the end of 2022[i] <#m_-7670270999625399876__edn1>
as government investments in the healthcare system and increasing levels of
medical tourism to the region drive growth in the industry.

CellPath intends to develop its presence in the Middle East and South Asia
by expanding its international distribution links and entering new
territories including Saudi Arabia, Lebanon, Egypt and Pakistan.

The company has just returned from the MEDLAB exhibition in Dubai where it
has met potential new distribution partners in Pakistan and further
strengthened its partnership with existing distribution partners in the
Middle East.

Advertisement

Simon Owen, Head of Exports at CellPath, said: “Naturally we are
continually looking for ways to grow the business and, with our export
strategy currently accounting for a third of group turnover, placing a
drive on international sales will be a key component to achieve this.

“We are already a market leader in the UK but our goal is to become a
market leader globally with some of the key products we manufacture here in
mid Wales. We plan to grow our exports by 20% over the next year and
expanding our distribution within the Middle East and South Asia will
significantly help with realising this goal.

“The Middle East is a growing life sciences market, with lots of
investments currently being made to hospitals and the medical sector in the
region. We already have a fantastic distributor covering the area, but
there is the opportunity for us to grow this partnership further as they
cover several countries across the UAE that we do not currently export to.
There is also the potential for us to secure additional distributors in
other new target markets, which is very exciting.”

CellPath has boasted an international outlook since it was first
established in 1990. Shortly after, the company began to attend its first
international trade shows such as Medica – the world’s biggest medical
trade show held in Dusseldorf – which allowed it to secure some of its
first overseas clients, and trade shows have remained a priority for the
business ever since.

Over the last five years, the company has placed a drive on international
sales, during which time its exports have doubled to account for around a
third of group turnover today. The firm has received support from the Welsh
Government, accessed via Business Wales, during this time to attend a
number of trade missions as well as visit new regions and conduct research
into target markets.

Following increased demand for its products and services overseas, the
company has invested over £2M in a new international distribution warehouse
and machinery at its Welsh headquarters to ensure it can meet orders. It
has also hired an additional six people across its export and regulatory
teams to ensure it remains compliant with local regulations in all
countries.

Simon added: “With the type of products that we offer, it’s important that
potential customers and distributors get to see them up close in person to
truly appreciate them. Attending trade shows and conducting market visits
is therefore an essential part of our export strategy.

“As well as allowing clients to see the quality of our products, face to
face interactions are vital to establishing and maintaining relationships,
as well as reinforcing our credibility as a business. We have been
extremely lucky to have received plenty of support from the Welsh
Government over the years to attend trade shows, research target markets,
and identify potential new clients and suppliers that they have connected
us with.

“This support has enabled us to secure a range of new business, helping us
with our growth trajectory.”

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.

Trending